Search
Coherus BioSciences Inc
CHRSAdd to Watchlist
1.160USD
0.0000.00%
Close 10-02 16:00（ET）
178.93MMarket Cap
0.71P/E TTM
Coherus BioSciences Inc (CHRS) Stock Price Target & Forecast
Analyst Rating
Based on 7 analysts giving stock ratings to Coherus BioSciences Inc in the past month.
Buy
3 Strong Buy
3 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
7.000USD+503.45%
CHRS Analyst Recommendation Trends
In the current month, CHRS has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. CHRS average Analyst price target in the last month is 7.000.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
3
3
2
2
2
2
1
1
3
3
3
3
3
3
3
3
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
7
6
6
6
6
5
5
CHRS Analyst Rating for Peer Comparison
Updated: Oct 4, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Amgen Inc
AMGN
4
12
18
2
1
37
Biogen Inc
BIIB
8
16
12
1
0
37
AbbVie Inc
ABBV
8
19
6
0
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Eli Lilly and Co
LLY
10
18
3
1
0
32
Merck & Co Inc
MRK
8
14
10
0
0
32
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Financial Forecasting
Based on analysts' estimates, CHRS EPS is projected to reach -0.220 in FY2026Q3, following reported EPS of -0.133 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.34
-0.27
-0.20
-0.22
-0.22
Actual
-0.31
-0.28
-0.13
--
--
Surprise
+8.94%
-2.80%
+33.37%
--
--
FAQs
What is Coherus BioSciences Inc's expected revenue for the next quarter?
Coherus BioSciences Inc's expected revenue is 16.01M.
What is Coherus BioSciences Inc's price target?
Analysts forecast that Coherus BioSciences Inc's price target is USD 7.00, with the highest forecast at USD 10.00 and the lowest forecast at USD 4.00.
How have Coherus BioSciences IncCHRS's recent earnings per share performed?
The market expectation was USD -0.13, while Coherus BioSciences IncCHRS's earnings per share (EPS) for the previous quarter was USD -0.28. EPS for the next quarter is expected at USD -0.22.
What is the analyst rating for Coherus BioSciences Inc?
Based on the ratings of Coherus BioSciences Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.